< Return
 

About Enzon

We are a biopharmaceutical company dedicated to the development of important medicines for patients with cancer.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing important medicines for patients with cancer. Enzon's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon's receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology.

Search

Enter your email address to sign up for the Enzon mailing list.


 
News
  • 05-06-2009

    Enzon Reaches Phase II Dose fo...

    Enzon Reaches Phase II Dose for PEG-SN38
    -- Composition of matter patent granted until 2027--

    click here for more information

  • 03-16-2009

    Enzon to Present at 29th Annua...

    Enzon to Present at 29th Annual Cowen and Company Conference

    click here for more information

  • 09-30-2008

    Enzon's New Oncaspar-IV™ Rec...

    Enzon's New Oncaspar-IV™ Receives Orphan Drug Status in the EU
    -- Improved version to expand global potential --

    click here for more information

  • 12-08-2008

    Enzon Pharmaceuticals Commence...

    Enzon Pharmaceuticals Commences Tender Offer For a Portion of its Debt

    click here for more information

  • 01-29-2010

    Enzon Completes Sale of Specia...

    Enzon Completes Sale of Specialty Pharmaceutical
    Business

    click here for more information

  • 04-23-2008

    Cimzia®, Utilizing Enzon's PE...

    Cimzia®, Utilizing Enzon's PEGylation Technology, Approved in the U.S.

    click here for more information

  • 07-29-2008

    Enzon to Release Second Quarte...

    Enzon to Release Second Quarter 2008 Earnings on Wednesday, August 6, 2008; Conference Call and Webcast to Follow

    click here for more information

  • 10-29-2007

    Enzon Initiates Second Phase 1...

    Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist

    click here for more information